Eagle Pharmaceuticals | Evaluate

Why some biotechs should never launch a drug

Acacia just became the latest biotech to suffer the curse of seeing one of its drugs approved.

November 11, 2021

The quest for efficacy in pancreatic cancer

Late-stage therapies from Fibrogen, Tyme and Novartis need to avoid the same pitfalls as Erytech and Rafael.

September 03, 2020

US FDA approval tracker: August 2020

August 04, 2020

US FDA approval tracker: July

July 01, 2020

Go or no go? Pandemic looms over FDA timelines

Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.

November 28, 2016

Returns hint at gradual decline in quality of biotech floats

April 10, 2015

Good times roll in Q1 as mid and small cap winners outnumber losers

April 03, 2014

Biotech floats hint at a narrowing gap between perception and reality

April 01, 2014

Biotech’s record-breaking quarter shines spotlight on sustainability